title: Systemic administration of ACTH or vasopressin reverses the amnestic effect of posttraining beta-endorphin or electroconvulsive shock but not that of intrahippocampal infusion of protein kinase inhibitors.
abstract: Retrograde amnesia was induced in rats trained in step-down inhibitory avoidance by four different treatments: an ip injection of beta-endorphin (1.0 microgram kg), an electroconvulsive shock (ECS), an intrahippocampal infusion of the calcium/calmodulin protein kinase II inhibitor, KN62 (0.08 microgram/side), given 0 h after training, or an intrahippocampal infusion of the protein kinase A inhibitor, KT5720 (0.5 microgram/side), given 3 h after training. Pretest ip injections of ACTH (0.2 microgram/kg) or vasopressin (10.0 micrograms/kg), but not saline, reversed the amnesia caused by beta-endorphin and ECS but not that caused by the enzyme inhibitors. This suggests that the amnesia produced by intrahippocampal KN62 and KT5720 administration is stronger than that caused by ECS and beta-endorphin, possibly because the former interfere directly with specific steps of the core biochemical chain of events that underlies memory consolidation.
authors.affiliation: Departamento de Bioquímica, Instituto de Ciencias Básicas da Saúde, UFRGS, Ramiro Barcellos, Brazil.
authors.forename: L A
authors.initials: LA
authors.lastname: Izquierdo
authors.forename: N
authors.initials: N
authors.lastname: Schröder
authors.forename: P
authors.initials: P
authors.lastname: Ardenghi
authors.forename: J
authors.initials: J
authors.lastname: Quevedo
authors.forename: C A
authors.initials: CA
authors.lastname: Netto
authors.forename: J H
authors.initials: JH
authors.lastname: Medina
authors.forename: I
authors.initials: I
authors.lastname: Izquierdo
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001143:Arousal / Q000187:drug effects* / Q000502:physiology; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D002227:Carbazoles; D003366:Cosyntropin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005239:Fear / Q000187:drug effects* / Q000502:physiology; D006624:Hippocampus / Q000187:drug effects* / Q000502:physiology; D007211:Indoles / Q000494:pharmacology*; D007274:Injections, Intraperitoneal; D008236:Lypressin / Q000494:pharmacology*; D008297:Male; D011939:Mental Recall / Q000187:drug effects*; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D011758:Pyrroles / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012153:Retention, Psychology / Q000187:drug effects / Q000502:physiology; D001615:beta-Endorphin / Q000037:antagonists & inhibitors* / Q000494:pharmacology
chemical_list: D002227:Carbazoles; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D003366:Cosyntropin; D008236:Lypressin; C057416:KT 5720; D001615:beta-Endorphin; C063302:KN 62; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D017871:Calcium-Calmodulin-Dependent Protein Kinases